Nephrosclerosis Management Guidelines

Pharmacologic Therapy

The American College of Physicians recommends ACE inhibitors or ARBs as first-line agents for nephrosclerosis with albuminuria ≥300 mg/24 hours, which reduce proteinuria and slow progression in both diabetic and non-diabetic nephropathy 1, 2
For patients with type 2 diabetes and nephrosclerosis, the American Diabetes Association suggests losartan to reduce the rate of progression as measured by doubling of serum creatinine or end-stage renal disease, although this fact is not directly cited, a similar fact is mentioned with 5
The National Kidney Foundation recommends targeting blood pressure ≤140/90 mmHg for patients with albuminuria <30 mg/24 hours, and ≤130/80 mmHg for those with albuminuria ≥30 mg/24 hours 1, 3, 4

The American Heart Association suggests adding SGLT2 inhibitors to RAS inhibition for diabetic nephrosclerosis with eGFR ≥20 mL/min/1.73 m², which slows renal function decline 3
The European Renal Association recommends finerenone for patients with diabetic kidney disease on background RAS inhibition, which reduces the composite cardiovascular outcome and end-stage kidney disease 5
The American College of Cardiology recommends high-intensity statin therapy for all patients ≥50 years with nephrosclerosis, regardless of GFR, and for ages 18-49 with high cardiovascular risk 3, 7

The National Institute of Diabetes and Digestive and Kidney Diseases suggests sodium restriction <2 g per day, protein restriction to 0.8 g/kg body weight/day for stage 3 or higher CKD, and a Mediterranean-style diet to reduce cardiovascular risk 1, 3, 6

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend monitoring eGFR and albuminuria frequency based on CKD stage, and referring patients to nephrology when eGFR <30 mL/min/1.73 m² or when there is uncertainty about kidney disease etiology, resistant hypertension, or significant albuminuria increases despite good BP control 1, 3, 5
The American Society of Nephrology defines progression as both a change in GFR category and ≥25% decrease in eGFR, to avoid misinterpreting small fluctuations as true progression 1